CICON 2025 Poster 131

A Novel In Vitro Assay to Evaluate the Potency of Anti-PD-1 and Anti-PD-L1 Drugs in NSCLC

Authors: Xuefei Yan, Sergei Chavez-Abiega, Tomas Veenendaal, Shiqi Guo, Jiawei Meng, Meng Zhang, Haijuan Yu, Jie Lin, Marrit Putker, Gera Goverse, Ludovic Bourre, Jun Zhou

Immune checkpoint inhibitors targeting PD-1/PD-L1 have transformed cancer treatment, yet predicting their efficacy requires physiologically relevant preclinical models.

In this study, Crown Bioscience presents a validated in vitro co-culture assay combining tumor cells or patient-derived organoids (PDOs) with activated immune cells to evaluate PD-1/PD-L1 blockade. Leveraging live-cell imaging, luminescence, and cytokine profiling, this platform enables precise measurement of tumor cell killing and immune activation, supporting the development and optimization of checkpoint inhibitors and combination strategies.

Download this Poster to Discover:

• Checkpoint Blockade Testing: Evaluate the potency of anti-PD-1 (pembrolizumab) and anti-PD-L1 (atezolizumab) in NSCLC tumor and organoid co-cultures.
  
  
• Dynamic Functional Readouts: Quantify tumor cell killing over time via live-cell imaging and luminescence.
  
  
• Immune Activation Insights: Measure cytokine release (e.g., IFN-γ) to assess immune response and potency.
  
  
• Predictive Preclinical Assay: A versatile system to accelerate the evaluation of novel checkpoint inhibitors and combinations.

Download the Poster Now!